151 related articles for article (PubMed ID: 18256879)
1. Correlation of mammographic calcifications with Her-2/neu overexpression in primary breast carcinomas.
Wang X; Chao L; Chen L; Tian B; Ma G; Zang Y; Hua M; Sun J
J Digit Imaging; 2008 Jun; 21(2):170-6. PubMed ID: 18256879
[TBL] [Abstract][Full Text] [Related]
2. Correlation of HER-2/neu overexpression with mammography and age distribution in primary breast carcinomas.
Seo BK; Pisano ED; Kuzimak CM; Koomen M; Pavic D; Lee Y; Cole EB; Lee J
Acad Radiol; 2006 Oct; 13(10):1211-8. PubMed ID: 16979070
[TBL] [Abstract][Full Text] [Related]
3. Mammographic features of calcifications in DCIS: correlation with oestrogen receptor and human epidermal growth factor receptor 2 status.
Bae MS; Moon WK; Chang JM; Cho N; Park SY; Won JK; Jeon YK; Moon HG; Han W; Park IA
Eur Radiol; 2013 Aug; 23(8):2072-8. PubMed ID: 23512196
[TBL] [Abstract][Full Text] [Related]
4. Primary breast carcinoma: association of mammographic calcifications with osteopontin expression.
Wang X; Chao L; Ma G; Chen L; Jin G; Hua M; Liu H; Ouyang A; Zhang X
Radiology; 2010 Jan; 254(1):69-78. PubMed ID: 20019131
[TBL] [Abstract][Full Text] [Related]
5. Mammographic morphology and distribution of calcifications in ductal carcinoma in situ diagnosed in organized screening.
Hofvind S; Iversen BF; Eriksen L; Styr BM; Kjellevold K; Kurz KD
Acta Radiol; 2011 Jun; 52(5):481-7. PubMed ID: 21498306
[TBL] [Abstract][Full Text] [Related]
6. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer.
Shin HJ; Kim HH; Huh MO; Kim MJ; Yi A; Kim H; Son BH; Ahn SH
Br J Radiol; 2011 Jan; 84(997):19-30. PubMed ID: 20682592
[TBL] [Abstract][Full Text] [Related]
7. Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics.
Gajdos C; Tartter PI; Bleiweiss IJ; Hermann G; de Csepel J; Estabrook A; Rademaker AW
Ann Surg; 2002 Feb; 235(2):246-51. PubMed ID: 11807365
[TBL] [Abstract][Full Text] [Related]
8. Qualitative Radiogenomics: Association Between BI-RADS Calcification Descriptors and Recurrence Risk as Assessed by the Oncotype DX Ductal Carcinoma In Situ Score.
Woodard GA; Price ER
AJR Am J Roentgenol; 2019 Apr; 212(4):919-924. PubMed ID: 30714832
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
[TBL] [Abstract][Full Text] [Related]
10. Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas.
Skandalis SS; Labropoulou VT; Ravazoula P; Likaki-Karatza E; Dobra K; Kalofonos HP; Karamanos NK; Theocharis AD
BMC Cancer; 2011 Jul; 11():314. PubMed ID: 21791066
[TBL] [Abstract][Full Text] [Related]
11. Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass.
Stomper PC; Geradts J; Edge SB; Levine EG
AJR Am J Roentgenol; 2003 Dec; 181(6):1679-84. PubMed ID: 14627596
[TBL] [Abstract][Full Text] [Related]
12. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
13. Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors.
Karamouzis MV; Likaki-Karatza E; Ravazoula P; Badra FA; Koukouras D; Tzorakoleftherakis E; Papavassiliou AG; Kalofonos HP
Int J Cancer; 2002 Nov; 102(1):86-90. PubMed ID: 12353238
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
15. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
Storm FK; Gilchrist KW; Warner TF; Mahvi DM
Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
[TBL] [Abstract][Full Text] [Related]
16. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
Tsai KB; Hou MF; Lin HJ; Chai CY; Liu CS; Huang TJ
Kaohsiung J Med Sci; 2001 Feb; 17(2):64-76. PubMed ID: 11416960
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
Spizzo G; Obrist P; Ensinger C; Theurl I; Dünser M; Ramoni A; Gunsilius E; Eibl G; Mikuz G; Gastl G
Int J Cancer; 2002 Apr; 98(6):883-8. PubMed ID: 11948467
[TBL] [Abstract][Full Text] [Related]
18. Zonula occludens-1 and Her-2/neu expression in invasive breast carcinoma.
Bell J; Walsh S; Nusrat A; Cohen C
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):125-9. PubMed ID: 12777995
[TBL] [Abstract][Full Text] [Related]
19. Correlation of mammographic appearance and molecular prognostic factors in high-grade breast carcinomas.
Likaki-Karatza E; Ravazoula P; Androutsopoulos G; Michail G; Batistatou A; Tzorakoleftherakis E; Kalofonos H; Kourounis G
Eur J Gynaecol Oncol; 2006; 27(1):39-41. PubMed ID: 16550966
[TBL] [Abstract][Full Text] [Related]
20. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
